On August 20, 2024, Kathleen Scott, Chief Financial Officer of ARS Pharmaceuticals Inc (SPRY, Financial), sold 12,500 shares of the company at a price of $16 per share. The transaction was filed on August 21, 2024, as reported in the SEC Filing. Following this transaction, the insider now owns 13,199 shares of ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is focused on developing and commercializing health solutions that leverage its novel formulation technology to address patient needs in various medical conditions.
Over the past year, the insider transaction history at ARS Pharmaceuticals Inc shows a trend with 6 insider buys and 33 insider sells. Kathleen Scott has sold a total of 12,500 shares and has not made any purchases in the same period.
The shares of ARS Pharmaceuticals Inc were trading at $16 on the day of the transaction, giving the company a market cap of approximately $1.299 billion.
For more detailed valuation metrics such as GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, investors can explore further details on the company's financial health and market standing.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
